<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Giordano C</submitter><funding>Telethon</funding><pagination>113</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4370040</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6</volume><pubmed_abstract>Mutations in mitochondrial (mt) DNA determine important human diseases. The majority of the known pathogenic mutations are located in transfer RNA (tRNA) genes and are responsible for a wide range of currently untreatable disorders. Experimental evidence both in yeast and in human cells has shown that the detrimental effects of mt-tRNA point mutations can be attenuated by increasing the expression of the cognate mt-aminoacyl-tRNA synthetases (aaRSs). In addition, constitutive high levels of isoleucyl-tRNA syntethase have been shown to reduce the penetrance of a homoplasmic mutation in mt-tRNA(Ile) in a small kindred. More recently, we showed that the isolated carboxy-terminal domain of human mt-leucyl tRNA synthetase (LeuRS-Cterm) localizes to mitochondria and ameliorates the energetic def</pubmed_abstract><journal>Frontiers in genetics</journal><pubmed_title>The phenotypic expression of mitochondrial tRNA-mutations can be modulated by either mitochondrial leucyl-tRNA synthetase or the C-terminal domain thereof.</pubmed_title><pmcid>PMC4370040</pmcid><funding_grant_id>GGP13097</funding_grant_id><pubmed_authors>Giordano C</pubmed_authors><pubmed_authors>d'Amati G</pubmed_authors><pubmed_authors>Perli E</pubmed_authors><pubmed_authors>Morea V</pubmed_authors></additional><is_claimable>false</is_claimable><name>The phenotypic expression of mitochondrial tRNA-mutations can be modulated by either mitochondrial leucyl-tRNA synthetase or the C-terminal domain thereof.</name><description>Mutations in mitochondrial (mt) DNA determine important human diseases. The majority of the known pathogenic mutations are located in transfer RNA (tRNA) genes and are responsible for a wide range of currently untreatable disorders. Experimental evidence both in yeast and in human cells has shown that the detrimental effects of mt-tRNA point mutations can be attenuated by increasing the expression of the cognate mt-aminoacyl-tRNA synthetases (aaRSs). In addition, constitutive high levels of isoleucyl-tRNA syntethase have been shown to reduce the penetrance of a homoplasmic mutation in mt-tRNA(Ile) in a small kindred. More recently, we showed that the isolated carboxy-terminal domain of human mt-leucyl tRNA synthetase (LeuRS-Cterm) localizes to mitochondria and ameliorates the energetic def</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015</publication><modification>2025-04-04T08:19:42.249Z</modification><creation>2019-03-27T01:48:39Z</creation></dates><accession>S-EPMC4370040</accession><cross_references><pubmed>25852750</pubmed><doi>10.3389/fgene.2015.00113</doi></cross_references></HashMap>